<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00309556</url>
  </required_header>
  <id_info>
    <org_study_id>ABCSG-24</org_study_id>
    <secondary_id>Ro 09-1978</secondary_id>
    <nct_id>NCT00309556</nct_id>
  </id_info>
  <brief_title>Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine in Early Breast Cancer</brief_title>
  <official_title>A Randomized Phase III Study Comparing Epirubicin, Docetaxel and Capecitabine + G-CSF to Epirubicin and Docetaxel + G-CSF as Neoadjuvant Treatment for Early HER-2 Negative Breast Cancer and Comparing Epirubicin, Docetaxel and Capecitabine + G-CSF ± Trastuzumab to Epirubicin and Docetaxel + G-CSF ± Trastuzumab as Neoadjuvant Treatment for Early HER-2 Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Austrian Breast &amp; Colorectal Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ebewe Pharma GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Austrian Breast &amp; Colorectal Cancer Study Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primarily, this clinical investigation compares the rates (percentages) of pathological
      complete remissions attained at the time of final surgery following 6 cycles each of
      epirubicin + docetaxel + capecitabine-containing chemotherapy ± trastuzumab (in HER-2
      positive disease) vs. epirubicin + docetaxel-containing chemotherapy ± trastuzumab (in HER-2
      negative disease).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, randomized, multicentre, phase III trial in the neoadjuvant
      treatment of patients with primary breast cancer and no distant metastases. Patients will be
      stratified at inclusion according to the centre, to the clinical tumour stage (T1, T2, T3,
      T4a-c), the axillary lymph node status (positive, negative), the menopausal status
      (pre-menopausal, post-menopausal), histology (invasive ductal, invasive lobular, mixed), the
      hormone-receptor status (positive [ER+/PR+, ER+/PR-, ER-/PR+], negative [ER-/PR-], not
      determinable]), the HER-2 status (positive, negative, not determinable), the grading (G1/G2,
      G3, not determinable) and will be randomly assigned to receive either 6 cycles of neoadjuvant
      epirubicin, docetaxel and capecitabine ± trastuzumab in HER-2 positive disease or 6 cycles of
      neoadjuvant epirubicin and docetaxel ± trastuzumab in HER-2 positive disease.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of pathological complete remissions</measure>
    <time_frame>20 weeks</time_frame>
    <description>at the time of final surgery after 6 cycles of Arm A (Epirubicin/ Docetaxel/ Capecitabine-containing chemotherapy ± Trastuzumab in HER-2 positive disease) vs. Arm B (Epirubicin/Docetaxel-containing chemotherapy ± Trastuzumab in HER-2 positive disease).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of axillary lymph node involvement and breast-conserving procedures</measure>
    <time_frame>20 weeks</time_frame>
    <description>at the time of final surgery in Arm A (± trastuzumab in HER-2 positive disease) vs. Arm B (± trastuzumab in HER-2 positive disease).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">536</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>A (experimental group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Epirubicin/Docetaxel/Capecitabine-containing chemotherapy ± trastuzumab in HER-2 positive disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B (control group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Epirubicin/Docetaxel-containing chemotherapy ± trastuzumab in HER-2 positive disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <description>6 cycles 75mg/m2 i.v. day 1 q3w</description>
    <arm_group_label>A (experimental group)</arm_group_label>
    <arm_group_label>B (control group)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>6 cycles 75mg/m2 i.v. day 1 q3w</description>
    <arm_group_label>A (experimental group)</arm_group_label>
    <arm_group_label>B (control group)</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>6 cycles 1000mg/m2 oral, day 1-14 q2d</description>
    <arm_group_label>A (experimental group)</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>cycle 1: 8mg/kg i.v. day 1 cycle 2-6: 6mg/kg i.v. day 1 (=6 cycles q3w)</description>
    <arm_group_label>A (experimental group)</arm_group_label>
    <arm_group_label>B (control group)</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients with histologically proven, core-biopsied, invasive breast cancer of
             any clinical and/or radiological T-stage (except for T4d)

          -  Age 18-70 years

          -  WHO performance status ≤ 2

          -  No prior or current neoplasm except for curatively treated non-melanoma skin cancer,
             in situ carcinoma of the cervix

          -  No distant disease / secondary carcinoma judged clinically and at least by chest
             X-ray, liver sonography, and bone scan upon randomization

          -  No medical and/or cardiologic contraindication to receive an anthracycline- and
             taxane-containing chemotherapy regimen. Normal cardiac function must be confirmed by
             LVEF (echocardiography or Muga scan). The result must be above 50% or above the
             institution's ULN

          -  Results of the following assessments at the time of randomization must be available:

               1. chest wall CT, abdomen CT, bilateral mammography: within 4 weeks before
                  enrolment;

               2. laboratory requirements: within 2 weeks before enrolment

               3. hematology: neutrophils ≥ 4.0 x 109/l, platelets ≥ 150 x 109/l, haemoglobin ≥ 13
                  g/dl

               4. hepatic function: total bilirubin &lt; 1 x ULN, ASAT (SGOT) and ALAT (SGPT) &lt; 1x
                  ULN, alkaline phosphatase &lt; 1 x ULN. In case of abnormal values, liver function
                  tests have to be repeated within 3 days before study treatment.

               5. renal function: creatinine ≤ 1 x ULN,

               6. histology, grading, hormone receptor status, HER-2/neu status

          -  Signed and dated informed consent before the start of specific protocol procedures

          -  Negative pregnancy test in the presence of childbearing potential

        Exclusion Criteria:

          -  Stage T4d / inflammatory breast cancer

          -  Pregnant or lactating patients; patients of childbearing potential must implement
             adequate contraceptive measures during study participation

          -  Pre-existing motor or sensory neurotoxicity of a severity ≥ WHO grade 2

          -  Preoperative local treatment for breast cancer (i.e. incomplete surgery, radiotherapy)

          -  Prior or concomitant systemic antitumor therapy

          -  Other serious illness or medical condition

               1. congestive heart failure or unstable angina pectoris, even if medically
                  controlled.

                  Previous history of myocardial infarction within 1 year from study entry,
                  uncontrolled hypertension or high-risk uncontrolled arrythmias

               2. history of significant neurologic or psychiatric disorders, including psychotic
                  disorders, dementia or seizures that would prohibit the understanding and giving
                  of informed consent

               3. active uncontrolled infection

               4. unstable peptic ulcer, unstable diabetes mellitus or other contraindication for
                  the use of corticosteroids

          -  Concurrent treatment with corticosteroids except as use for the prophylactic regimen,
             inhalational use, treatment of acute hypersensitivity reactions, treatment of
             nausea/vomiting or chronic treatment (initiated &gt; 6 months prior to study entry) at
             low dose (≤ 20 mg methylprednisolone or equivalent)

          -  Known hypersensitivity against taxanes and/or epirubicin and/or
             fluorouracil/capecitabine

          -  Known dihydropyrimidine-dehydrogenase (DPD) deficit

          -  Treatment with an investigational drug within 30 days prior to study entry

          -  Legally incapacitated and/or other circumstances which make it unfeasible for the
             subject to understand the nature, meaning and consequences of the clinical study

          -  Concurrent psychiatric illness according to ICD (alcohol addiction) at the time of
             study entry
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guenther Steger, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Austrian Breast &amp; Colorectal Cancer Study Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Guessing</name>
      <address>
        <city>Guessing</city>
        <state>Burgenland</state>
        <zip>7540</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Oberpullendorf</name>
      <address>
        <city>Oberpullendorf</city>
        <state>Burgenland</state>
        <zip>7350</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Oberwart</name>
      <address>
        <city>Oberwart</city>
        <state>Burgenland</state>
        <zip>7400</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Hospital Klagenfurt</name>
      <address>
        <city>Klagenfurt</city>
        <state>Carinthia</state>
        <zip>9026</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ordination Dr. Wette</name>
      <address>
        <city>St. Veit a. d. Glan</city>
        <state>Carinthia</state>
        <zip>9300</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital BHB St. Veit/Glan, Surgery</name>
      <address>
        <city>St. Veit a. d. Glan</city>
        <state>Carinthia</state>
        <zip>9330</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Hospital Villach</name>
      <address>
        <city>Villach</city>
        <state>Carinthia</state>
        <zip>9500</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Hospital Wolfsberg</name>
      <address>
        <city>Wolfsberg</city>
        <state>Carinthia</state>
        <zip>9400</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Baden</name>
      <address>
        <city>Baden bei Wien</city>
        <state>Lower Austria</state>
        <zip>2500</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Krems</name>
      <address>
        <city>Krems</city>
        <state>Lower Austria</state>
        <zip>3500</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Wiener Neustadt</name>
      <address>
        <city>Wiener Neustadt</city>
        <state>Lower Austria</state>
        <zip>2700</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gynaegological Medical University Graz</name>
      <address>
        <city>Graz</city>
        <state>Styria</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Graz, Oncology</name>
      <address>
        <city>Graz</city>
        <state>Styria</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Hospital Leoben</name>
      <address>
        <city>Leoben</city>
        <state>Styria</state>
        <zip>8700</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <state>Tyrol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>District Hospital Kufstein</name>
      <address>
        <city>Kufstein</city>
        <state>Tyrol</state>
        <zip>6330</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Hospital Kirchdorf</name>
      <address>
        <city>Kirchdorf</city>
        <state>Upper Austria</state>
        <zip>4560</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital BHS Linz</name>
      <address>
        <city>Linz</city>
        <state>Upper Austria</state>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Linz</name>
      <address>
        <city>Linz</city>
        <state>Upper Austria</state>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Hospital Steyr</name>
      <address>
        <city>Steyr</city>
        <state>Upper Austria</state>
        <zip>4400</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Wels-Grieskirchen</name>
      <address>
        <city>Wels</city>
        <state>Upper Austria</state>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Hospital Feldkirch/Rankweil</name>
      <address>
        <city>Rankweil</city>
        <state>Vorarlberg</state>
        <zip>6807</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paracelsus Medical University Salzburg - Oncology</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University Vienna, General Hospital</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Hospital Vienna-Hietzing</name>
      <address>
        <city>Vienna</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanusch Hospital</name>
      <address>
        <city>Vienna</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>http://www.abcsg.at</url>
    <description>Click here for more information about this study: ABCSG-Studien closed</description>
  </link>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2006</study_first_submitted>
  <study_first_submitted_qc>March 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2006</study_first_posted>
  <last_update_submitted>December 29, 2011</last_update_submitted>
  <last_update_submitted_qc>December 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epirubicin</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Herceptin</keyword>
  <keyword>Breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

